Jinhyun Cho

Correction: Evidence‑based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions

Sung‐Hoon Jung, Young‐Il Koh, Min Kyoung Kim, Jin Seok Kim et autres

kr, jp, us (code pays fourni par la source)

Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions

Sung‐Hoon Jung, Young‐Il Koh, Min Kyoung Kim, Jin Seok Kim et autres

Multiple myeloma (MM), a hematological malignancy, is characterized by malignant plasma cell proliferation in the bone marrow. Recent treatment advances have significantly improved patient outcomes associated with MM. In this study, we aimed to develop comprehensive, evidence-based guidelines for the diagnosis, prognosis, …

kr (code pays fourni par la source)

Relative efficacy of systemic treatments for patients with relapsed/refractory chronic lymphocytic leukemia: a network meta-analysis according to 17p deletion/TP53 mutations

Jin‐Chul Kim, Jinhyun Cho, Joo Han Lim, Moon Hee Lee

PURPOSE: This network meta-analysis aimed to evaluate the relative efficacy of systemic treatments in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), focusing on key genetic mutations, specifically the 17p deletion and TP53 mutations. METHODS: We conducted a systematic literature review to …

kr (code pays fourni par la source)

Relative Efficacy of Systemic Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis According to 17p Deletion/TP53 Mutations

Jinchul Kim, Jinhyun Cho, Joo Han Lim, Moon Hee Lee et autres

Introduction: The treatment landscape forrelapsed/refractory chronic lymphocytic leukemia (R/R CLL) has significantly advanced with the introduction of novel targeted therapies. Although these treatments have shown improved outcomes for R/R CLL patients, no single standard of care has been established. This network meta-analysis …

kr (code pays fourni par la source)

The Risk and Reversibility of Osimertinib-Related Cardiotoxicity in a Real-World Population

Minjung Bak, Hyukjin Park, Se‐Hoon Lee, Nuri Lee et autres

kr (code pays fourni par la source)

CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis

Jinchul Kim, Jinhyun Cho, Moon Hee Lee, Sang Eun Yoon et autres

ABSTRACT: This meta-analysis evaluates the efficacy and safety of chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). We searched MEDLINE, Embase, and Cochrane databases until July 2023 for trials assessing CAR T-cell therapies …

kr (code pays fourni par la source)

THU107 A Case Of Primary Histiocytic Sarcoma Of Pituitary Gland Presenting With Central Diabetes Insipidus

Seong Hee Ahn, Youngjoon Kim, Yongin Cho, Da Hea Seo et autres

Abstract Disclosure: S. Ahn: None. Y. Kim: None. Y. Cho: None. D. Seo: None. S. Kim: None. J. Cho: None. S. Choi: None. K. Kim: None. E. Kim: None. S. Hong: None. Introduction: Histiocytic sarcoma is a rare and aggressive hematopoietic neoplasm …

kr (code pays fourni par la source)

Supplementary Figure S1 from The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh et autres

Supplementary Figure S1

Supplementary Tables from The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh et autres

Supplementary Tables S1-S7

Supplementary Tables from The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh et autres

Supplementary Tables S1-S7

Supplementary Figure S1 from The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh et autres

Supplementary Figure S1

Data from The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh et autres

AbstractPurpose: To investigate blood-based dynamic biomarkers that predict responses to anti–programmed cell death protein 1 (PD-1) therapy in solid tumors. Experimental Design: Preplanned biomarker analysis was performed as part of a phase II clinical trial (NCT02607631) in patients with metastatic or refractory …